Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of PPI on Palbociclib Tablet Bioavailability
NCT03220191Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Pfizer. Primary endpoints: Area Under the Curve from time 0 to infinity and Maximum Plasma Concentration. Started Jul 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03220191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220191.